Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism that contributes to treatment failure in acute myeloid leukemia (AML). They show that there are not just one, but four different subtypes of leukemia stem cells. This diversity could explain why one of the most important AML drugs does not work sufficiently in some patients or loses its effectiveness over time—resulting in the return of leukemia. This discovery lays an important foundation for more precise and long-term successful treatment strategies that could specifically overcome resistance mechanisms.

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the launch of JAYseq^TM, a clinical whole-genome sequencing (WGS) test specifically for multiple myeloma. Approximately 35,000 new cases of multiple myeloma are diagnosed annually in the U.S., making it the second-most common blood cancer. The JAYseq test, developed and performed by TGen Clinical Laboratory, a CAP‑accredited lab founded by TGen, is intended for patients with newly diagnosed multiple myeloma, relapsed or refractory disease, or related plasma cell disorders.

A new study shows that cancer cells are better able to resist treatments when they have an abnormal number of chromosomes.

Since a landmark 2009 study, researchers have known that a common gut bacterium, Bacteroides fragilis, drives colon tumor formation, potentially leading to colorectal cancer, by secreting a toxin that damages the lining of the colon. But until now, the exact mechanism the toxin uses to latch onto those cells remained a mystery.

A study presented at the ESMO Breast Cancer 2026 congress examines whether an efficiently delivered genetic testing can identify gPV carriers among previously untested patients, enabling prevention, earlier screening, and family risk assessment, while supporting a sustainable healthcare delivery model.